IL-12 serum levels in patients with type 2 diabetes treated with sulphonylureas
Introduction
Interleukin-12 (IL-12)—a cytokine produced by antigen presenting cells like dendritic cells (DC), macrophages and natural killer (NK) cells—plays a critical role in cell-mediated immunity. IL-12 affects a variety of stages in the immune response: it prompts NK cells and T cells to produce pro-inflammatory cytokines, such as IFN-γ (interferon-γ), IL-2, IL-3 and TNF-α (tumor necrosis factor-α); it contributes to NK cell maturation [1], [2]; and, along with other pro-inflammatory factors, it stimulates CD4+CD25− T cell activation in the presence of regulatory T cells [3]. IL-12 also regulates naïve T cell differentiation into T helper type 1 lymphocytes (Th1), and inhibits differentiation into T helper type 2 lymphocytes (Th2) [1], [4]. It has been documented that increased systemic inflammatory activity in patients with CAD (coronary artery disease) is associated with a prominent Th1 response [5].
Current data suggest that IL-12 plays a critical role in the pathogenesis of type 1 diabetes [1], [6], but the significance of IL-12 changes in the blood of patients with type 2 diabetes remains unclear. It has been observed that IL-12 plasma concentrations are elevated in type 2 diabetics [7], and that IL-12 contributes to the process of atherosclerotic plaque formation and probably accelerates the development of macrovascular complications in type 2 diabetics, as well [8], [9]. Additionally, it has been noted that elevated glucose levels in diabetic animals stimulates inflammatory reactions related to IL-12 cytokine gene expression [10]. However, it is not known whether factors related to the course of type 2 diabetes, such as metabolic compensation, beta cell secretory dysfunction, and insulin resistance affect IL-12 concentrations.
Therefore, the present study was undertaken to assess the relationship between metabolic control, insulin resistance and IL-12 concentrations in the sera of type 2 diabetics.
Section snippets
Study groups
Basal studies were performed in the Department of Pharmacology at Poznan University of Medical Sciences, on 41 type 2 diabetic patients (19 women and 22 men). Their mean age was 66.8 years (range 33–85 years). The mean duration of diabetes was 7.7 years (range 0.5–19 years). All patients were being treated with gliclazide [Diaprel; Servier, twice daily 80 mg (31) or Diaprel MR; Servier, 30 mg daily (7)] or with glimepiride [Amaryl; Aventis Pharma, 2 mg twice daily (3)]. Therapeutic regimen for
Results
The characteristics of all the subjects, including diabetic patients, CAD patients and healthy controls are shown in Table 1, Table 2. Diabetic patients and patients with CAD were similar, in terms of body mass index and lipid profile. Patients without overt carbohydrate metabolism deterioration (healthy subjects and patients with CAD) had lower levels of fasting glycaemia than diabetics. Plasma 1,5-AG concentrations were significantly lower in diabetic patients versus either control group. The
Discussion
Currently available data about the pathogenesis of type 2 diabetes demonstrate that a very important feature of this disease is chronic inflammation [23], [24]. IL-12 is a pro-inflammatory cytokine, but its role in the pathogenesis and course of diabetes still is being assessed [2], [25]. It is well known that high levels of IL-12 in serum can stimulate T lymphocytes and NK cells proliferation and migration to atherosclerosis plaques [26], [27]. Moreover, Th1 predominance related to IL-12 high
References (44)
- et al.
Regulatory mechanisms and their therapeutic implications of interleukin-12 production in immune cells
Cell Signal
(2005) - et al.
Interleukin 12—an integral cytokine in the immune response
Life Sci
(1996) - et al.
IL-12 and IL-10 polymorphisms and their effects on cytokine production
Cytokine
(2005) - et al.
Oxidised LDL modulates immune-activation by an IL-12 dependent mechanism
Atherosclerosis
(2003) - et al.
Concentrations of interleukins, interferon, and C-reactive protein in stable and unstable angina pectoris
Am J Cardiol
(2003) - et al.
Human resistin stimulates the pro-inflammatory cytokines TNF-alpha and IL-12 in macrophages by NF-kappaB-dependent pathway
Biochem Biophys Res Commun
(2005) - et al.
Activation and suppression of renin-angiotensin system in human dendritic cells
Biochem Biophys Res Commun
(2002) Function and clinical use of interleukin-12
Curr Opin Hematol
(1997)- et al.
Cutting edge. IL-12 induces CD4+CD25− T cell activation in the presence of T regulatory cells
J Immunol
(2005) - et al.
Increased Th1 activity in patients with coronary disease
Cytokine
(2004)
Aberrant regulation of interleukin-12 receptor 2 chain on type 1 cytokine stimulated T lymphocytes in type 1 diabetes
Immunology
Increased interleukin-12 plasma concentrations in both, insulin-depended and non-insulin-depended diabetes mellitus
Diabetologia
Cross-regulatory roles of interleukin-(12) and IL-10 in atherosclerosis
J Clin Invest
Blockade of interleukin-12 function by protein vaccination attenuates atherosclerosis
Circulation
Elevated glucose and diabetes promote interleukin-12 cytokine gene expression in mouse macrophages
Endocrinology
International federation of clinical chemistry and laboratory medicine (IFCC). Approved IFCC reference method for the measurement of HbA1c in human blood
Clin Chem Lab Med
Use of GHb (HbA1c) in screening for undiagnosed diabetes in the US population
Diabetes Care
Simple enzymatic method for determining 1,5-anhydro-d-glucitol for diagnosis of diabetes mellitus
Clin Chem
The application of enzymatic method for 1,5-anhydro-d-glucitol estimation in plasma
Diagnostyka Laboratoryjna
The application of plasma 1,5-anhydro-d-glucitol (1,5-AG) for monitoring type 2 diabetic patients
Dis Markers
Cited by (57)
Pathophysiological correlation of arginase-1 in development of type 2 diabetes from obesity in adolescents
2023, Biochimica et Biophysica Acta - General SubjectsAmygdalin alleviates renal injury by suppressing inflammation, oxidative stress and fibrosis in streptozotocin-induced diabetic rats
2021, Life SciencesCitation Excerpt :IFN-γ and IL-12, as important pro-inflammatory factors, are involved in the inflammatory pathological damage process in diabetic nephropathy models. For example, high glucose can induce an increase in the expression of IFN-γ and IL-12, and serum levels IFN-γ and IL-12 are obviously up-regulated in the patients with = diabetes compare to normal controls [15–17]. We thereby detected the serum and renal level of IFN-γ and IL-12 to evaluate the occurrence of inflammation in DN rats.
Toll-like Receptor Signaling Rewires Macrophage Metabolism and Promotes Histone Acetylation via ATP-Citrate Lyase
2019, ImmunityCitation Excerpt :We identified IL-12 as a cytokine that is most affected by Acly inhibition and that is highly sensitive to perturbations of glucose metabolism. Indeed, IL-12 serum concentrations associate with diabetes and are increased in sera of patients with type I and type II diabetes and metabolic syndrome (Schmidt et al., 2015; Suárez-Álvarez et al., 2013; Winkler et al., 1998; Wegner et al., 2008). In light of these findings, future investigations should be directed to determine, for example, how high blood glucose or chronic hyperglycemia affects the epigenetic landscape of macrophages in vivo.
Association of IL-10 to coronary disease severity in patients with metabolic syndrome
2019, Clinica Chimica ActaTLR-induced secretion of novel cytokine IL-27 is defective in newly diagnosed type-2 diabetic subjects
2018, CytokineCitation Excerpt :Even though IL-27 has largely been implicated in autoimmune diseases [11], its role in chronic inflammatory conditions like type-2 diabetes is largely unknown. Serum levels of IL-12 [14], IL-23 [15], IL-27 [16], IL-8 [17] and IL-17 [18] were found to be altered in Type-2 diabetes. However, the effect of type-2 diabetes on TLR-induced secretion of these cytokines is not known.
Essential Role of IL-12 in Angiogenesis in Type 2 Diabetes
2017, American Journal of PathologyCitation Excerpt :The HFD mice model is a robust and efficient model for impaired glucose tolerance and progressive insulin resistance and type 2 diabetes.2,15 In agreement with previous studies, we showed that p40−/− and p35−/− mice were unable to produce a biological active of IL-12,21,22 the heterodimeric cytokine IL-12 (70 kDa) composed of p35 (35 kDa) and p40 (40 kDa) (Figure 4 A), and IL-12 production is enhanced in obese type 2 diabetic patients and animal models.11,13,14,26 We found an increase of IL-12 in the hind-limb muscle of our diabetic mice (fed an HFD for 12 weeks) compared with nondiabetic mice (fed a chow diet).